Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ono-8539. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 2/20 | 0.33 |
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.33 |
| ▸ | EP300 | Q09472 | 1/20 | 0.33 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.33 |
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 2/20 | 0.32 |
| ▸ | RXRB | P28702 | 2/20 | 0.32 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RXRG | P48443 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ono-8539 SCHEMBL29572731 | 1.00 | MCL1 (0.33) | MCL1TRPM8EP300NLRP3KDM5A | |
| SCHEMBL15456470 | 0.92 | NLRP3 (0.34) | EP300NLRP3NPC1RAB9A | |
| SCHEMBL215320 | 0.90 | MCL1 (0.36) | MCL1EP300KDM5AKDM4CKDM5B | |
| SCHEMBL213550 | 0.90 | NLRP3 (0.34) | TRPM8NLRP3KDM5AKDM4CKDM5B | |
| SCHEMBL214578 | 0.90 | MCL1 (0.35) | MCL1EP300KDM5AKDM4CKDM5B | |
| SCHEMBL215919 | 0.89 | RXRB (0.44) | TRPM8EP300RXRARXRBNPC1 | |
| SCHEMBL213408 | 0.88 | MCL1 (0.34) | MCL1TRPM8RXRARXRBMRGPRX4 | |
| SCHEMBL214486 | 0.87 | RECQL (0.35) | EP300RAB9A | |
| SCHEMBL214485 | 0.87 | RECQL (0.35) | EP300RAB9A | |
| SCHEMBL212682 | 0.84 | MCL1 (0.35) | MCL1RXRARXRBMRGPRX4NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181187-B2 | Therapeutic agent for urinary excretion disorder | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-11-10 | — | — | US | claimed |
| EP-2881115-A1 | MEDICINE AGAINST GASTROESOPHAGEAL REFLUX DISEASE | ONO Pharmaceutical Co., Ltd. (JP) | 2015-06-10 | — | — | EP | claimed |
| US-20140039004-A1 | METHOD OF TREATING OF GASTROESOPHAGEAL REFLUX DISEASE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-02-06 | — | — | US | claimed |
| EP-2123273-B1 | THERAPEUTIC AGENT FOR URINARY EXCRETION DISORDER | ONO PHARMACEUTICAL CO (JP) | 2013-10-23 | — | — | EP | claimed |
| EP-1612208-B1 | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation | ONO PHARMACEUTICAL CO (JP) | 2011-08-31 | — | — | EP | claimed |
| US-20100076038-A1 | THERAPEUTIC AGENT FOR URINARY EXCRETION DISORDER | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-03-25 | — | — | US | claimed |
| EP-2123273-A1 | THERAPEUTIC AGENT FOR URINARY EXCRETION DISORDER | ONO Pharmaceutical Co., Ltd. (JP) | 2009-11-25 | — | — | EP | claimed |
| US-7335776-B2 | Remedies for depression containing EP1 antagonist as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-02-26 | — | — | US | claimed |
| US-7235667-B2 | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-06-26 | — | — | US | claimed |
| EP-1369419-B1 | N-PHENYLARYLSULFONAMIDE COMPOUND, DRUG CONTAINING THE COMPOUND AS ACTIVE INGREDIENT, INTERMEDIATE FOR THE COMPOUND, AND PROCESSES FOR PRODUCING THE SAME | ONO PHARMACEUTICAL CO (JP) | 2007-05-23 | — | — | EP | claimed |
| US-20060030713-A1 | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation | ONO PHARMACEUTICAL CO., LTD. | 2006-02-09 | — | — | US | claimed |
| EP-1612208-A2 | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-04 | — | — | EP | claimed |
| US-20050124672-A1 | N-phenylarylsulfonamide compound drug containing the compound as active ingredient intermediate for the compound and processes for producing the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-09 | — | — | US | claimed |
| EP-1369419-A1 | N-PHENYLARYLSULFONAMIDE COMPOUND, DRUG CONTAINING THE COMPOUND AS ACTIVE INGREDIENT, INTERMEDIATE FOR THE COMPOUND, AND PROCESSES FOR PRODUCING THE SAME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-12-10 | — | — | EP | claimed |
| CN-104519883-B | Medicine against gastroesophageal reflux disease | 小野药品工业株式会社 | 2017-05-10 | — | — | CN | disclosed |
| US-9181187-B2 | Therapeutic agent for urinary excretion disorder | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-11-10 | — | — | US | disclosed |
| EP-2881115-A1 | MEDICINE AGAINST GASTROESOPHAGEAL REFLUX DISEASE | ONO Pharmaceutical Co., Ltd. (JP) | 2015-06-10 | — | — | EP | disclosed |
| US-20040082653-A1 | Remedies for depression containing ep1 antagonist as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1369419-A1 | N-PHENYLARYLSULFONAMIDE COMPOUND, DRUG CONTAINING THE COMPOUND AS ACTIVE INGREDIENT, INTERMEDIATE FOR THE COMPOUND, AND PROCESSES FOR PRODUCING THE SAME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-12-10 | — | — | EP | disclosed |
| EP-1369129-A1 | REMEDIES FOR DEPRESSION CONTAINING EP1 ANTAGONIST AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030713-A1 | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation | PTGER1, PTGER2, PTGES | MCL1 3209/4885TRPM8 150/4885EP300 408/4885 |
| US-20140039004-A1 | METHOD OF TREATING OF GASTROESOPHAGEAL REFLUX DISEASE | HRH2, GRPR, MLNR | MCL1 4885/4885TRPM8 887/4885EP300 2479/4885 |
| US-20100076038-A1 | THERAPEUTIC AGENT FOR URINARY EXCRETION DISORDER | PTGER1, TMPRSS15, EPDR1 | MCL1 4224/4885TRPM8 1357/4885EP300 1573/4885 |
| US-20050124672-A1 | N-phenylarylsulfonamide compound drug containing the compound as active ingredient intermediate for the compound and processes for producing the same | PTGER1, PTGER2, PTGES | MCL1 2506/4885TRPM8 130/4885EP300 437/4885 |
| US-20040082653-A1 | Remedies for depression containing ep1 antagonist as the active ingredient | PTGER1, PTGER2, PTGS1 | MCL1 4177/4885TRPM8 145/4885EP300 742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.